Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Travere Therapeutics (NASDAQ: TVTX) recently:

• 8/17/2026 – Travere Therapeutics had its “overweight” rating reaffirmed by Piper Sandler.
• 8/10/2026 – Travere Therapeutics was given a new $78.00 price target by Evercore Inc.
• 8/6/2026 – Travere Therapeutics had its price target raised by Wedbush from $61.00 to $75.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Travere Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $62.00 to $70.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Travere Therapeutics had its “outperform” rating reaffirmed by Evercore Inc.
• 8/5/2026 – Travere Therapeutics had its price target raised by Guggenheim from $65.00 to $75.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Travere Therapeutics had its price target raised by Citigroup Inc. from $70.00 to $85.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Travere Therapeutics had its price target raised by TD Cowen from $60.00 to $75.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Travere Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $56.00 to $62.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Travere Therapeutics had its price target raised by Guggenheim from $56.00 to $65.00. They now have a “buy” rating on the stock.
• 6/23/2026 – Travere Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/22/2026 – Travere Therapeutics had its price target raised by Wedbush from $55.00 to $61.00. They now have an “outperform” rating on the stock.

Insiders Place Their Bets

In other news, Director Roy D. Baynes sold 4,500 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $50.00, for a total value of $225,000.00. Following the sale, the director directly owned 41,500 shares of the company’s stock, valued at $2,075,000. This represents a 9.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Timothy Coughlin sold 10,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $50.07, for a total transaction of $500,700.00. Following the transaction, the director owned 56,250 shares of the company’s stock, valued at $2,816,437.50. This represents a 15.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.44% of the stock is owned by insiders.

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.